Table 1 Dose volume constraints in SCOPE 1 trial
From: The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial
Region of interest/Organ at risk | Dose constraint |
|---|---|
PTV | V95 % (47.5Gy) > 99.0 % |
PTV | PTV min > 93 % (46.5Gy) |
DMAX | <107 % |
GTV | GTV min > 100 % (50.0Gy) |
Spinal cord PRV | Cord Max <80 % (40Gy) |
Combined lungs | V40 % (V20Gy) < 25 % |
Heart | V80 % (V40Gy) < 30 % |
Liver | V60 % (V30Gy) < 60 % |
Individual kidneys | V40 % (V20Gy) < 25 % |